Fibroblast growth factor 21 (FGF21) is one of the members of endocrine arm of FGF family. Its actions as a glucose and lipids metabolism regulator are widely known. Although the mechanism of FGF21 action in kidneys is still under investigation, FGF21 was considered as a marker of early kidney function decline. While many researchers focused on adult subjects in this matter, there are no data regarding children. Therefore, we have investigated the relationship between plasma or urine FGF21 levels and kidney function in a group of 42 pediatric patients with chronic kidney disease (CKD). Anthropometrical parameters and blood pressure were taken, routine biochemical tests were performed. The concentration of FGF21 in serum and urine was determined by enzyme immunoassay. The results revealed significantly higher serum FGF21 concentration among children from CKD group. However, serum FGF21 level was not related to gender, proteinuria, eGFR or renal replacement therapy. Urine FGF21 concentration correlated negatively with albuminuria and positively with eGFR. Documented negative correlation of FGF21 fractional excretion and eGFR is not enough to support the role of FGF21 as a biomarker for predicting kidney disease progression in children and adolescents. Other mechanisms including local kidney FGF21 production or enhanced excretion due to higher extrarenal production may result in higher urine FGF21 concentrations.

Unit of Paediatric Hematology and Oncology Chorzow City Hospital Chorzow Poland; Department of Pediatrics Faculty of Medical Sciences in Zabrze Medical University of Silesia in Katowice Zabrze Poland or

Zobrazit více v PubMed

ADAMS AC, CHENG CC, COSKUN T, KHARITONENKOV A. FGF21 requires βklotho to act in vivo. PLoS One. 2012;7:e49977. doi: 10.1371/journal.pone.0049977. PubMed DOI PMC

ANDERSEN B, BECK-NIELSEN H, HØJLUND K. Plasma FGF21 displays a circadian rhythm during a 72-h fast in healthy female volunteers. Clin Endocrinol (Oxf) 2011;75:514–519. doi: 10.1111/j.1365-2265.2011.04084.x. PubMed DOI

ANGELIN B, LARSSON TE, RUDLING M. Circulating fibroblast growth factors as metabolic regulators—a critical appraisal. Cell Metab. 2012;16:693–705. doi: 10.1016/j.cmet.2012.11.001. PubMed DOI

ANUWATMATEE S, TANG S, WU B, RYE K-A, ONG K. Fibroblast growth factor 21 in chronic kidney disease. Clin Chim Acta. 2019;489:196–202. doi: 10.1016/j.cca.2017.11.002. PubMed DOI

ANUWATMATEE S, ALLISON M, SHLIPAK M, McCLELLAND R, KRAMER H, TANG S, HOU L, RYE K, ONG K. Relationship of fibroblast growth factor 21 with kidney function and albuminuria: multi-ethnic study of atherosclerosis. Nephrol Dial Transplant. 2019;34:1009–1016. doi: 10.1093/ndt/gfy120. PubMed DOI PMC

BAEK J, NAM HK, RHIE YJ, LEE KH. Serum FGF21 levels in obese Korean children and adolescents. J Obes Metab Syndr. 2017;26:204–209. doi: 10.7570/jomes.2017.26.3.204. PubMed DOI PMC

BISGAARS A, SØRENSEN K, JOHANNSEN T, HELGE J, ANDERSSON AM, JUUL A. Significant gender difference in serum levels of fibroblast factor 21 in Danish children and adolescents. Int J Pediatr Endocrinol. 2014;7:2014. doi: 10.1186/1687-9856-2014-7. PubMed DOI PMC

CRASTO C, SEMBA R, SUN K, FERRUCCI L. Serum fibroblast growth factor 21 is associated with renal function and chronic kidney disease in community-dwelling adults. J Am Geriatr Soc. 2012;60:792–793. doi: 10.1111/j.1532-5415.2011.03879.x. PubMed DOI PMC

CRUMP C, SUNDQUIST J, WINKLEBY MA, SUNDQUIST K. Preterm birth and risk of chronic kidney disease from childhood into mid-adulthood: national cohort study. BMJ. 2019;365:l1346. doi: 10.1136/bmj.l1346. PubMed DOI PMC

CZARNIAK P, KRÓL E, SZCZEŚNIAK P. Wybrane aspekty epidemiologiczne przewlekłej choroby nerek u dzieci i młodzieży. (In Polish) Forum Nefrol. 2010;1:45–50.

GOSPODAROWICZ D. Purification of a fibroblast growth factor from bovine pituitary. J Biol Chem. 1975;250:2515–2520. PubMed

HARAMBAT J, STRALEN KJ, KIM JJ, TIZARD EJ. Epidemiology of chronic kidney disease in children. Pediatr Nephrol. 2012;27:363–373. doi: 10.1007/s00467-011-1939-1. PubMed DOI PMC

HINDRICKS J, EBERT T, BACHMANN A, KRALISCH S, LÖSSNER U, KRATZSCH J, STOLZENBURG JU, DIETEL A, BEIGE J, ANDERS M, BAST I, BLÜHER M, STUMVOLL M, FASSHAUER M. Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction. Clin Endocrinol (Oxf) 2014;80:918–924. doi: 10.1111/cen.12380. PubMed DOI

INAGAKI T. Research perspectives on the regulation and physiological functions of FGF21 and its association with NAFLD. Front Endocrinol (Lausanne) 2015;6:147. doi: 10.3389/fendo.2015.00147. PubMed DOI PMC

INAGAKI T, LIN VY, GOETZ R, MOHAMMADI M, MANGELSDORF D, KLIEWER S. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab. 2008;8:77–83. doi: 10.1016/j.cmet.2008.05.006. PubMed DOI PMC

ITOH N. Hormone-like (endocrine) FGFs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res. 2010;342:1–11. doi: 10.1007/s00441-010-1024-2. PubMed DOI PMC

ITOH N, OHTA H, KONISHI M. Endocrine FGFs: evolution, physiology, pathophysiology, and pharmacotherapy. Front Endocrinol. 2015;6:154. doi: 10.3389/fendo.2015.00154. PubMed DOI PMC

KHARITONENKOV A, Di MARCHI R. FGF21 revolutions: recent advances illuminating FGF21 biology and medicinal properties. Trends Endocrinol Metab. 2015;26:608–617. doi: 10.1016/j.tem.2015.09.007. PubMed DOI

KDIGO 2012 Clinical Practice Guideline for Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements. 2013;3:19–62. PubMed

KOHARA M, MASUDA T, SHIIZAKI K, AKIMOTO T, WATANABE Y, HONMA S, SEKIGUCHI C, MIYAZAWA Y, KUSANO E, KANDA Y, ASANO Y, KURO-O M, NAGATA D. Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease. PLoS One. 2017;12:e0178971. doi: 10.1371/journal.pone.0178971. PubMed DOI PMC

KOKKINOS J, TANG S, RYE KA, ONG KL. The role of fibroblast growth factor 21 in atherosclerosis. Atherosclerosis. 2017;257:259–265. doi: 10.1016/j.atherosclerosis.2016.11.033. PubMed DOI

KOSOLA S, LAMPELA H, GYLLING H, JALANKO H, NISSINEN MJ, LAURONEN J, MÄKISALO H, VAARALAHTI K, MIETTINEN TA, RAIVIO T, PAKARINEN MP. Cholesterol metabolism altered and FGF21 levels high after pediatric liver transplantation despite normal serum lipids. Am J Transplant. 2012;12:2815–2824. doi: 10.1111/j.1600-6143.2012.04147.x. PubMed DOI

KREJCI E, PESEVSKI Z, NANKA O, SEDMERA D. Physiological role of FGF signaling in growth and remodeling of developing cardiovascular system. Physiol Res. 2016;65:425–435. doi: 10.33549/physiolres.93321. PubMed DOI

LEE CH, HUI EY, WOO YC, YEUNG CY, CHOW WS, YUEN MM, FONG CH, XU A, LAM KS. Circulating fibroblast factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria. J Clin Endocrinol Metabol. 2015;100:1368–1375. doi: 10.1210/jc.2014-3465. PubMed DOI

LIANG Q, ZHONG L, ZHANG J, WANG Y, BORNSTEIN SR, TRIGGLE CR, DING H, LAM KS, XU A. FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting. Diabetes. 2014;63:4064–4075. doi: 10.2337/db14-0541. PubMed DOI

LIU JJ, FOO JP, LIU S, LIM SC. The role of fibroblast growth factor 21 in diabetes and its complications: A review from clinical perspective. Diabetes Res Clin Pract. 2015;108:382–389. doi: 10.1016/j.diabres.2015.02.032. PubMed DOI

MIAN AN, SCHWARTZ GJ. Measurement and estimation of glomerular filtration rate in children. Adv Chronic Kidney Dis. 2017;24:348–356. doi: 10.1053/j.ackd.2017.09.011. PubMed DOI PMC

ORNITZ DM, ITOH N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4:215–266. doi: 10.1002/wdev.176. PubMed DOI PMC

SUASSUNA PG, De PAULA R, SANDERS-PINHEIRO H, MOE O, HU M-C. Fibroblast growth factor 21 in chronic kidney disease. J Nephrol. 2018;32:365–377. doi: 10.1007/s40620-018-0550-y. PubMed DOI PMC

SZYMCZYK A, KRZYWAŃSKI R, FORMA E. Struktura i funkcja białak βKlotho. (In Polish) Folia Medica Lodz. 2013;40:99–132.

WARADY BA, CHADHA V. Chronic kidney disease in children: the global perspective. Pediatr Nephrol. 2007;22:1999–2009. doi: 10.1007/s00467-006-0410-1. PubMed DOI PMC

ZHANG J, WU H, MA S, JING F, YU C, GAO L, ZHAO J. Transcription regulators and hormones involved in the development of brown fat and white fat browning: transcriptional and hormonal control of brown/beige fat development. Physiol Res. 2018;67:347–362. doi: 10.33549/physiolres.933650. PubMed DOI

Assessment of Zinc- alpha2 glycoprotein (ZAG) and Lipase Maturation Factor 1 (LMF1) concentration in children with chronic kidney disease